TABLE 1.
Clinical characteristics of patients with chronic HCV infection and treated with ribavirin-interferon combination therapya
| Patients characteristic | All patients (n = 24) | Responders (n = 11) | Nonresponders (n = 13) |
|---|---|---|---|
| Mean (minimum-maximum) age (yr) | 44.3 (24-67) | 39 (24-67) | 49 (35-62) |
| Mean (minimum-maximum) wt (kg) | 73.8 kg (50-112) | 76 (50-112) | 72 (51-100) |
| Mean (minimum-maximum) Knodell score | 9.7 (4-15) | 9.5 (6-15) | 9.5 (4-15) |
| Mean (minimum-maximum) Métavir | |||
| Activity | 2.0 (1-3) | 2 (1-3) | 2 (1-3) |
| Fibrosis | 2.1 (0-4) | 2.1 (1-3) | 2 (0-4) |
| Mean (minimum-maximum) ALAT (ULN)b | 2.2 (0.94-4.7) | 2.3 (0.9-4.1) | 2.1 (0.9-1.7) |
| Mean (minimum-maximum) viral load IU/ml | 1,238,767 IU/ml (8,000-5,078,650) | 1,126,218 IU/ml (8,000-3,160,000) | 1,334,000 IU/ml (111,300-5,078,650) |
| Ribavirin dose (mg/day) | 1,000 (n = 9), 1,200 (n = 2) | 600 (n = 2, adjusted for adverse effects), 1,000 (n = 8), 1,200 (n = 3) |
a
All patients were infected with genotype 1 HCV isolates and were drug naive and receiving their first standard combination therapy.
b
ALAT, alanine aminotransferase; ULN, upper limit of normality.